534 Ixabepilone, a novel tubulin interacting agent, given every other week in combination with irinotecan in patients with advanced malignancies: a phase i and pharmacokinetic study

S.Faivre; C.Delbaldo; P.Pautier; V.Boige; S.Henriet; F.Namouni; C.Eyndels; R.Peck; J.Armand; E.Raymond

首页> 外文期刊>European Journal of Cancer Supplements >534 Ixabepilone, a novel tubulin interacting agent, given every other week in combination with irinotecan in patients with advanced malignancies: a phase i and pharmacokinetic study

【24h】

534 Ixabepilone, a novel tubulin interacting agent, given every other week in combination with irinotecan in patients with advanced malignancies: a phase i and pharmacokinetic study

机译：534 Ixabepilone，一种新型的微管蛋白相互作用剂，每隔一周与伊立替康联合治疗晚期恶性肿瘤患者：I期和药代动力学研究

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2004年第8期|共1页
作者
S.Faivre; C.Delbaldo; P.Pautier; V.Boige; S.Henriet; F.Namouni; C.Eyndels; R.Peck; J.Armand; E.Raymond;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies. [J] . Faivre S, Delbaldo C, Boige V, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2008,第5期

机译：晚期恶性肿瘤患者每隔3周一次输注ixabepilone与irinotecan联合3小时输注的安全性。
2. A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies. [J] . Plummer R, Woll P, Fyfe D, Clinical cancer research: an official journal of the American Association for Cancer Research . 2008,第24期

机译：ixabepilone联合卡铂治疗晚期实体恶性肿瘤的I期和药代动力学研究。
3. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors [J] . Montero Alberto J., Kwon Deukwoo, Flores Aurea, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第13期

机译：晚期实体瘤患者每周或每三周伊沙贝比隆和每日舒尼替尼的I期临床，药代动力学和药效学研究
4. Designing a conversational agent for patients with hematologic malignancies: Usability and Usefulness Study [C] . Maria Chatzimina, Helen Papadaki, Charalampos Pontikoglou, IEEE EMBS International Conference on Biomedical and Health Informatics . 2021

机译：设计血液学恶性肿瘤患者的会话剂：可用性和有用性研究
5. Use and outcomes of newer chemotherapeutic agents in colorectal cancer patients using Irinotecan as a case study. [D] . Obeidat, Nour A. 2008

机译：以伊立替康为例的结直肠癌患者中新型化疗药物的使用和结果。
6. A Phase I Clinical Pharmacokinetic and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors [O] . Alberto J. Montero, Deukwoo Kwon, Aurea Flores, -1

机译：晚期实体瘤患者每周或每三周伊沙贝比隆和每日舒尼替尼的I期临床药代动力学和药效学研究
7. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors [O] . Alberto J. Montero, Deukwoo Kwon, Aurea Flores, 2016

机译：一期临床，药代动力学和药效学研究每周或每三周Ixabepilone和晚期阳光患者的晚期实体瘤患者

534 Ixabepilone, a novel tubulin interacting agent, given every other week in combination with irinotecan in patients with advanced malignancies: a phase i and pharmacokinetic study

著录项

相似文献

相关主题

期刊订阅